ANXA7

Across TCGA pan-cancer cohorts, ANXA7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANXA7 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANXA7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANXA7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, COAD, and HNSC are the cancer types where ANXA7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.634	0.313	.001	29	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.018	18	view →
HNSC	DFS	Quartile	III,IV	1.000	0.857	.016	12	view →
LUAD	DFS	Quartile	II,III,IV	0.258	0.588	.010	11	view →
UCEC	DFS	Median	All	0.951	0.857	.026	4	view →
LSCC	DFS	Tertile	III,IV	0.543	0.979	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANXA7–PDAC (OS)

Open the PDAC breakdown →